NEW MJ NEWS

AbbVie to Present at the Bernstein 38th Annual Strategic Decisions Conference

AbbVie (NYSE: ABBV) will participate in the Bernstein 38th Annual Strategic Decisions Conference on Wednesday, June 1, 2022. Richard A. Gonzalez, chairman and chief executive officer, will present at 10:00 a.m. Central Time.

A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-present-at-the-bernstein-38th-annual-strategic-decisions-conference-301554489.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Canopy Growth Corporation (CGC) Partner with Martha Stewart and Marquee Brands

Martha Stewart and Marquee Brands Partner with Canopy Growth Corporation to Launch…

$HEMP Reports: South Dakota on Track to Legalize Industrial Hemp

“Industrial hemp has absolutely no recreational applications. It only has medical and…

$EXMT as Equipment and Services Supplier.

Apache Moving Forward With Indoor Medical Cannabis Facility. Frontier Indoor Garden Solutions…

GT Biopharma (OXISD) Announces Development Plan For Non-Opioid Neuropathic Pain Treatment “PainBrake”

LOS ANGELES, CA / ACCESSWIRE / September 11, 2017 / GT Biopharma…